CD8A and neoplasm: Three of these 6 patients experienced an objective tumor response, including one sunitinib-treated patient, showing strong intratumoral infiltration of CD8+ T cells in the removed tumor, who responded with a complete and durable regression (> 52 months, still ongoing) of 4 brain metastases (and also all liver metastases) (Fig. 4).